Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Gastrointestinal Motility Disorders01:20

Gastrointestinal Motility Disorders

Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...
Histology of the Gastrointestinal (GI) Tract01:20

Histology of the Gastrointestinal (GI) Tract

The GI tract, from beginning to end, is made up of four continuous tissue layers that adjust their structure according to their specific roles. These layers, from innermost to outermost, are known as the mucosa, submucosa, muscularis, and serosa, which are continuous with the mesentery.
The mucosa is sometimes called a mucous membrane due to its mucus-secreting features. This membrane is composed of epithelium, which directly interacts with ingested substances, and the lamina propria, a layer...
Stomach Histology01:26

Stomach Histology

The stomach comprises several layers that work together to facilitate digestion and protect the organ. The outermost layer is called the serosa, which provides support and protection to the stomach. The muscularis externa layer is responsible for the mechanical breakdown of food by contracting and moving the stomach. The submucosa layer, located beneath the muscularis externa, contains connective tissue, blood vessels, nerves, and glands that secrete mucus and other substances essential for...
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term outcome of patients with idiopathic membranous nephropathy.

Prague medical report·2006
Same author

Daily oral versus pulse intravenous cyclophosphamide in the therapy of ANCA-associated vasculitis--preliminary single center experience.

Prague medical report·2004
Same author

[Bartter syndrome or renal tubular acidosis?].

Sbornik lekarsky·2004
Same author

[An unusual cause of acute anuric renal failure].

Vnitrni lekarstvi·2004
Same author

[Fibrillary glomerulonephritis].

Sbornik lekarsky·2003
Same author

[Kidney involvement in light-chain deposition disease].

Sbornik lekarsky·2003

Related Experiment Video

Updated: May 31, 2026

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

[Gastrointestinal stromal tumors].

J Zabka1

  • 1Chirurgicke oddelení, Klatovská nemocnice, a. s., Klatovy. jirizabka@seznam.cz

Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti
|July 2, 2011
PubMed
Summary

Gastrointestinal stromal tumours (GISTs) are rare mesenchymal tumors. Targeted therapies like imatinib are revolutionizing GIST treatment by inhibiting KIT or PDGFRA pathways, improving outcomes for patients.

Area of Science:

  • Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal (GI) tract.

Context:

  • GISTs are rare, accounting for 1% of all primary GI cancers, and can occur anywhere in the alimentary tract, omentum, mesentery, or peritoneum.
  • Tumor size, mitotic rate, and anatomic location (intestinal vs. gastric) influence the malignant potential of GISTs.

Purpose:

  • To outline the current understanding and therapeutic strategies for GISTs.
  • To highlight the role of targeted therapies in managing GISTs.

Summary:

  • Mutational activation of KIT or PDGFRA drives GIST growth via aberrant receptor tyrosine kinase signaling.
  • Treatment involves surgical resection for GISTs ≥ 2 cm.
  • Small molecule inhibitors (imatinib, sunitinib) target these pathways.
  • Adjuvant imatinib is recommended for high-risk patients post-resection.

More Related Videos

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Related Experiment Videos

Last Updated: May 31, 2026

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

  • Neoadjuvant therapy is indicated for unresectable or metastatic GISTs to facilitate resection and organ preservation.

    • Impact:

    • Targeted therapies have revolutionized GIST treatment by specifically inhibiting oncogenic signaling pathways.
    • Improved surgical outcomes and organ preservation are achievable with neoadjuvant and adjuvant therapeutic strategies.